|1.||Parada, Carlos Amílcar: 3 articles (12/2010 - 01/2009)|
|2.||Tambeli, Cláudia Herrera: 3 articles (12/2010 - 01/2009)|
|3.||Pelegrini-da-Silva, Adriana: 3 articles (12/2010 - 01/2009)|
|4.||Oliveira, Maria Cláudia G: 2 articles (10/2010 - 01/2009)|
|5.||Kamei, Junzo: 2 articles (10/2006 - 12/2005)|
|6.||Takahashi, Yoshiki: 2 articles (10/2006 - 12/2005)|
|7.||Liu, Ting-Ting: 1 article (11/2015)|
|8.||Rao, Zhiguo: 1 article (11/2015)|
|9.||Qiu, Chun-Yu: 1 article (11/2015)|
|10.||Gan, Xiong: 1 article (11/2015)|
11/15/2015 - "And the mechanical allodynia induced by PK2 was prevented by co-administration of TNP-ATP, a selective P2X receptor antagonist. "
01/01/2011 - "The mechanical allodynia was significantly attenuated by peripheral administration of the P2X receptor antagonists, PPADS or TNP-ATP. "
03/13/2009 - "Intrathecal administration of P2X receptor antagonists (PPADS and TNP-ATP) inhibited the mechanical allodynia in diabetic mice. "
05/01/2012 - "The peripheral expression of P2X3 receptor in dermal nerves was accordingly increased (p=0.016), and an intraplantar injection of the P2X3 antagonists, A-317491 and TNP-ATP, relieved mechanical allodynia in a dose-dependent manner. "
09/26/2014 - "We found that 2'(3')-O-(4-benzoylbenzoyl)adenosine 5'-triphosphate triethylammonium salt (BzATP), the most potent P2X7 receptor agonist available, induced a dose-dependent mechanical hyperalgesia that was blocked by the P2X7 receptor-selective antagonist A-438079 but unaffected by the P2X1,3,2/3 receptor antagonist TNP-ATP. "
01/01/2009 - "Furthermore, peripherally administered TNP-ATP could exert an analgesic effect on this pain model. "
03/01/2002 - "Furthermore, 2'-(or-3')-O-(trinitrophenyl)adenosine 5'- tri-phosphate (TNP-ATP) potently (IC50=10 nM) blocked the functional activation of P2X3 receptors in vitro and attenuated acetic acid-induced visceral pain. "
12/01/1999 - "3. Capsaicin-induced nociceptive behaviour that has been shown to be a model for neurogenic pain, was also significantly suppressed by intrathecal pretreatment with PPADS or TNP-ATP. "
12/01/1999 - "5. These findings suggest that spinal endogenous ATP may play a role in (1) the formalin- and capsaicin-induced neurogenic pain via the PPADS- and TNP-ATP-sensitive P2X receptors which are also desensitized by alpha,betameATP (perhaps the P2X3 receptor subtype) and (2) formalin-induced inflammatory pain via PPADS-sensitive, TNP-ATP- and alpha,betameATP-insensitive P2X (and/or P2Y) receptors."
12/28/2005 - "ATP-induced enhancement of the number of citric acid-induced coughs was abolished when animals were pretreated with 2',3'-O-(2,4,6-trinitrophenyl) adenosine 5-triphosphate (TNP-ATP), an antagonist of P2X receptor subtypes P2X1-4, at a concentration of 50 microM, for 2 min. However, exposure to pyridoxal-phosphate-6-azophenyl-2',4'-disulphonic acid (PPADS), an antagonist of P2X receptor subtypes P2X1,2,3,5,7, but not of P2X4 receptors, at a concentration of 50 microM, for 2 min, had no effect on the ATP-induced enhancement of the number of citric acid-induced coughs. "
10/10/2006 - "The histamine-induced increase in the number of citric acid-induced coughs was completely reduced when animals were co-pretreated with 2',3'-O-(2,4,6-trinitrophenyl) adenosine 5-triphosphate (TNP-ATP, 50 microM), a P2X receptor antagonist, and reactive blue 2, a P2Y receptor antagonist, for 2 min. Furthermore, the ATP-induced increase in the number of citric acid-induced coughs was dose dependently and significantly decreased when animals were pretreated with fexofenadine, at doses of 0.3, 1 and 3 mg/kg, p.o. "
|5.||Neuralgia (Stump Neuralgia)
|1.||Purinergic P2X3 Receptors
|4.||pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid
|5.||Adenosine Triphosphate (ATP)
|6.||Purinergic P2X7 Receptors
|7.||Citric Acid (Citrate)